Bioventus, Inc. (BVS)
| Market Cap | 1.05B |
| Revenue (ttm) | 324.29M |
| Net Income (ttm) | n/a |
| Shares Out | 41.80M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | 12.17 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $18.42 |
| Previous Close | $17.63 |
| Change ($) | 0.79 |
| Change (%) | 4.48% |
| Day's Open | 18.00 |
| Day's Range | 17.67 - 18.60 |
| Day's Volume | 226,216 |
| 52-Week Range | 10.74 - 19.51 |
As of late, it has definitely been a great time to be an investor of Bioventus (BVS).
DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Ca...
DURHAM, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three ...
Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution
DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fis...
DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc. (“Bioness”), a...
DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the ...
DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enr...
DURHAM, N.C., March 04, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Larry Chen as Managing Dire...
DURHAM, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that fourth quarter and f...
Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering...
DURHAM, N.C.--Bioventus Inc. ("Bioventus" or the “Company”), today announced that it has commenced the initial public offering of its Class A common stock. Bioventus is offering 7,350,000 shares of its ...
RESEARCH TRIANGLE PARK - Biotech companies continue to jump in line to join the public markets. Bioventus, a medical device maker whose portfolio includes...
This is the second time North Carolina medical device maker applied to go public via an initial public offering. In 2016, the company rescinded its application citing market conditions.
Bioventus, which offers orthobiologics products for musculoskeletal conditions, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company had previously file...
Bioventus, Inc. has filed to go public with an IPO on the NASDAQ.
About BVS
Bioventus is a global medical device company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body’s natural healing process. We believe our non-invasive medical device and biologic products play a critical role in supporting the body’s own healing mechanisms to heal or eliminate the pain caused by orthopedic conditions and problems, which we define as our active healing products. These products address an estimated $6.0 billion market opportuni... [Read more...]
| Industry Diagnostics & Research | IPO Date Feb 11, 2021 |
| CEO Kenneth M. Reali | Employees 900 |
| Stock Exchange NASDAQ | Ticker Symbol BVS |
Financial Performance
In 2020, Bioventus's revenue was $321.16 million, a decrease of -5.58% compared to the previous year's $340.14 million. Earnings were $16.41 million, an increase of 139.54%.
Analyst Forecasts
The average 12-month stock price forecast for Bioventus is 20.67, which is an increase of 12.21% from the latest price.